

Matteo Lazzeroni

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3430773/publications.pdf>

Version: 2024-02-01

83
papers

1,830
citations

318942

23
h-index

325983

40
g-index

87
all docs

87
docs citations

87
times ranked

2925
citing authors

#	ARTICLE	IF	CITATIONS
1	A Randomized Trial of Robotic Mastectomy Versus Open Surgery in Women With Breast Cancer or BrCA Mutation. <i>Annals of Surgery</i> , 2022, 276, 11-19.	2.1	36
2	Advances and controversies in management of breast ductal carcinoma in situ (DCIS). <i>European Journal of Surgical Oncology</i> , 2022, 48, 736-741.	0.5	10
3	A Model to Predict Upstaging to Invasive Carcinoma in Patients Preoperatively Diagnosed with Low-Grade Ductal Carcinoma In Situ of the Breast. <i>Cancers</i> , 2022, 14, 370.	1.7	6
4	Response to Braillon. <i>JNCI Cancer Spectrum</i> , 2021, 5, pkab005.	1.4	0
5	Complete Removal of the Lesion as a Guidance in the Management of Patients with Breast Ductal Carcinoma In Situ. <i>Cancers</i> , 2021, 13, 868.	1.7	9
6	Effect Modifiers of Low-Dose Tamoxifen in a Randomized Trial in Breast Noninvasive Disease. <i>Clinical Cancer Research</i> , 2021, 27, 3576-3583.	3.2	10
7	A Meta-Analysis of Obesity and Risk of Colorectal Cancer in Patients with Lynch Syndrome: The Impact of Sex and Genetics. <i>Nutrients</i> , 2021, 13, 1736.	1.7	10
8	Atypical Ductal Hyperplasia after Vacuum-Assisted Breast Biopsy: Can We Reduce the Upgrade to Breast Cancer to an Acceptable Rate?. <i>Diagnostics</i> , 2021, 11, 1120.	1.3	13
9	A Novel Automated Immunoassay Platform to Evaluate the Association of Adiponectin and Leptin Levels with Breast Cancer Risk. <i>Cancers</i> , 2021, 13, 3303.	1.7	8
10	Patientâ€ versus physicianâ€ reported outcomes in a lowâ€ dose tamoxifen trial in noninvasive breast cancer. <i>Breast Journal</i> , 2021, 27, 817-823.	0.4	4
11	Prognostic impact of genetic variants of CYP19A1 and UGT2B17 in a randomized trial for endocrine-responsive postmenopausal breast cancer. <i>Pharmacogenomics Journal</i> , 2020, 20, 19-26.	0.9	8
12	De-Escalating Treatment of Low-Risk Breast Ductal Carcinoma In Situ. <i>Journal of Clinical Oncology</i> , 2020, 38, 1252-1254.	0.8	8
13	Development of an HPLC-MS/MS Method for the Determination of Silybin in Human Plasma, Urine and Breast Tissue. <i>Molecules</i> , 2020, 25, 2918.	1.7	1
14	Is tumor testing efficiency for Lynch syndrome different in rectal and colon cancer?. <i>Digestive and Liver Disease</i> , 2020, 52, 1503-1511.	0.4	1
15	Prognostic and predictive value of cell cycle progression (CCP) score in ductal carcinoma in situ of the breast. <i>Modern Pathology</i> , 2020, 33, 1065-1077.	2.9	3
16	Low-Dose Aspirin in High-Risk Individuals With Screen-Detected Subsolid Lung Nodules: A Randomized Phase II Trial. <i>JNCI Cancer Spectrum</i> , 2020, 4, pkaa096.	1.4	3
17	Abstract OT1-04-03: Alternative dosing of exemestane before surgery in postmenopausal patients with stage 0-II estrogen receptor positive breast cancer: Design and methodology. , 2020, , .		1
18	Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS. <i>Breast</i> , 2019, 44, S6.	0.9	0

#	ARTICLE	IF	CITATIONS
19	Ductal carcinoma in situ and intraoperative partial breast irradiation: Who are the best candidates? Long-term outcome of a single institution series. <i>Radiotherapy and Oncology</i> , 2019, 133, 68-76.	0.3	9
20	Randomized Placebo Controlled Trial of Low-Dose Tamoxifen to Prevent Local and Contralateral Recurrence in Breast Intraepithelial Neoplasia. <i>Journal of Clinical Oncology</i> , 2019, 37, 1629-1637.	0.8	143
21	Estimating the magnitude of clinical benefit of systemic therapy in patients with DCIS or pre-invasive disease of the breast. <i>Breast</i> , 2019, 48, S39-S43.	0.9	4
22	The risk of extra-ovarian malignancies among women with endometriosis: A systematic literature review and meta-analysis. <i>Critical Reviews in Oncology/Hematology</i> , 2019, 134, 72-81.	2.0	32
23	Effect modifiers in a randomized phase III trial of low-dose tamoxifen in breast preinvasive disease.. <i>Journal of Clinical Oncology</i> , 2019, 37, 1500-1500.	0.8	3
24	Adjuvant therapy in patients with ductal carcinoma in situ of the breast: The Pandora's box. <i>Cancer Treatment Reviews</i> , 2017, 55, 1-9.	3.4	21
25	A Presurgical Study of Lecithin Formulation of Green Tea Extract in Women with Early Breast Cancer. <i>Cancer Prevention Research</i> , 2017, 10, 363-370.	0.7	56
26	The prevalence and clinical relevance of tumor-infiltrating lymphocytes (TILs) in ductal carcinoma in situ of the breast. <i>Annals of Oncology</i> , 2017, 28, 321-328.	0.6	72
27	Circulating and tissue biomarkers in early-stage non-small. <i>Ecancermedicalsecience</i> , 2017, 11, 717.	0.6	19
28	Benefit of low-dose tamoxifen in a large observational cohort of high risk ER positive breast DCIS. <i>International Journal of Cancer</i> , 2016, 139, 2127-2134.	2.3	30
29	A Randomized, Placebo-Controlled, Phase II, Presurgical Biomarker Trial of Celecoxib Versus Exemestane in Postmenopausal Breast Cancer Patients. <i>Cancer Prevention Research</i> , 2016, 9, 349-356.	0.7	14
30	Alternate dosing schedules for cancer chemopreventive agents. <i>Seminars in Oncology</i> , 2016, 43, 116-122.	0.8	14
31	A Presurgical Study of Oral Silybin-Phosphatidylcholine in Patients with Early Breast Cancer. <i>Cancer Prevention Research</i> , 2016, 9, 89-95.	0.7	35
32	Molecular biomarkers in early-stage lung cancer.. <i>Journal of Clinical Oncology</i> , 2016, 34, e23082-e23082.	0.8	0
33	Abstract 1788: Benefit of low-dose tamoxifen in a large, single-institution cohort of high-risk ER-positive DCIS. , 2016, , .		0
34	Abstract CT122: A presurgical study of lecithin formulation of green tea extract in women with early breast cancer. , 2016, , .		0
35	Risk of subsequent in situ and invasive breast cancer in human epidermal growth factor receptor 2-positive ductal carcinoma in situ. <i>Annals of Oncology</i> , 2015, 26, 682-687.	0.6	51
36	Cancer chemoprevention: Much has been done, but there is still much to do. State of the art and possible new approaches. <i>Molecular Oncology</i> , 2015, 9, 1008-1017.	2.1	24

#	ARTICLE	IF	CITATIONS
37	Long-term effects of inhaled budesonide on screening-detected lung nodules. <i>Annals of Oncology</i> , 2015, 26, 1025-1030.	0.6	19
38	Effect of Metformin on Breast Ductal Carcinoma <i>In Situ</i> Proliferation in a Randomized Presurgical Trial. <i>Cancer Prevention Research</i> , 2015, 8, 888-894.	0.7	23
39	Metformin: risk-benefit profile with a focus on cancer. <i>Expert Opinion on Drug Safety</i> , 2015, 14, 1573-1585.	1.0	18
40	Abstract P5-12-02: Metformin decreases Ki67 in HER2+ve ductal carcinoma in situ in a window of opportunity trial. , 2015, , .		0
41	Breast conservative surgery for well-differentiated ductal intraepithelial neoplasia: Risk factors for ipsilateral breast tumor recurrence. <i>Breast</i> , 2014, 23, 829-835.	0.9	9
42	Association of molecular subtypes with Ki-67 changes in untreated breast cancer patients undergoing pre-surgical trials. <i>Annals of Oncology</i> , 2014, 25, 618-623.	0.6	28
43	Differential effects of metformin on breast cancer proliferation according to markers of insulin resistance and tumor subtype in a randomized presurgical trial. <i>Breast Cancer Research and Treatment</i> , 2014, 148, 81-90.	1.1	65
44	A presurgical study of oral silybin-phosphatidylcholine in patients with early breast cancer.. <i>Journal of Clinical Oncology</i> , 2014, 32, 2580-2580.	0.8	0
45	Differential effects of metformin on breast cancer proliferation according to insulin resistance and tumor subtype in a presurgical trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 599-599.	0.8	0
46	Aspirin and Breast Cancer Prevention. <i>Current Breast Cancer Reports</i> , 2013, 5, 202-207.	0.5	4
47	Breast Cancer Prevention by Antihormones and Other Drugs. <i>Hematology/Oncology Clinics of North America</i> , 2013, 27, 657-672.	0.9	16
48	A randomized phase II presurgical trial of weekly low-dose tamoxifen versus raloxifene versus placebo in premenopausal women with estrogen receptor-positive breast cancer. <i>Breast Cancer Research</i> , 2013, 15, R47.	2.2	23
49	The effect of metformin on apoptosis in a breast cancer presurgical trial. <i>British Journal of Cancer</i> , 2013, 109, 2792-2797.	2.9	72
50	Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials. <i>Anti-Cancer Agents in Medicinal Chemistry</i> , 2013, 13, 118-125.	0.9	35
51	Effect of low-dose tamoxifen after surgical excision of ductal intraepithelial neoplasia: results of a large retrospective monoinstitutional cohort study. <i>Annals of Oncology</i> , 2013, 24, 1859-1866.	0.6	18
52	A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. <i>Annals of Oncology</i> , 2013, 24, 2753-2760.	0.6	28
53	Acceptability of chemoprevention trials in high-risk subjects. <i>Annals of Oncology</i> , 2013, 24, viii42-viii46.	0.6	7
54	Tailoring treatment for ductal intraepithelial neoplasia of the breast according to Ki-67 and molecular phenotype. <i>British Journal of Cancer</i> , 2013, 108, 1593-1601.	2.9	38

#	ARTICLE	IF	CITATIONS
55	Metformin effects on cancer adjacent breast preneoplasia in a randomized pre-surgical trial.. Journal of Clinical Oncology, 2013, 31, 1517-1517.	0.8	0
56	Vitamin D supplementation and cancer: review of randomized controlled trials. Anti-Cancer Agents in Medicinal Chemistry, 2013, 13, 118-25.	0.9	19
57	Dual Effect of Metformin on Breast Cancer Proliferation in a Randomized Presurgical Trial. Journal of Clinical Oncology, 2012, 30, 2593-2600.	0.8	218
58	Prognostic Effect of Circulating Adiponectin in a Randomized 2 Å– 2 Trial of Low-Dose Tamoxifen and Fenretinide in Premenopausal Women at Risk for Breast Cancer. Journal of Clinical Oncology, 2012, 30, 151-157.	0.8	63
59	Potential Use of Vaccines in the Primary Prevention of Breast Cancer in High-Risk Patients. Breast Care, 2012, 7, 281-287.	0.8	11
60	Oral low dose and topical tamoxifen for breast cancer prevention: modern approaches for an old drug. Breast Cancer Research, 2012, 14, 214.	2.2	63
61	Breast ductal lavage for biomarker assessment in high risk women: rationale, design and methodology of a randomized phase II clinical trial with nimesulide, simvastatin and placebo. BMC Cancer, 2012, 12, 575.	1.1	5
62	Vitamin D Supplementation and Cancer: Review of Randomized Controlled Trials. Anti-Cancer Agents in Medicinal Chemistry, 2012, 13, 118-125.	0.9	2
63	A phase III prevention trial of low-dose tamoxifen in HRT users: The HOT trial.. Journal of Clinical Oncology, 2012, 30, 1500-1500.	0.8	1
64	Abstract 2664: Biological relevance of CYP2D6 phenotype and low dose tamoxifen activity within a randomized phase II pre-surgical trial.. , 2012, , .		0
65	Abstract 3561: Effects of metformin on markers of insulin resistance and on breast cancer proliferation: The putative role of IGFBP-1 as a predictive biomarker. , 2012, , .		0
66	Dual effects of metformin on breast cancer proliferation in a randomized trial.. Journal of Clinical Oncology, 2012, 30, 519-519.	0.8	6
67	Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention Trial. Pharmacogenomics Journal, 2011, 11, 100-107.	0.9	62
68	The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. Breast, 2011, 20, S36-S41.	0.9	19
69	Lapatinib Activity in Premalignant Lesions and HER-2 Positive Cancer of the Breast in a Randomized, Placebo-Controlled Presurgical Trial. Cancer Prevention Research, 2011, 4, 1181-1189.	0.7	52
70	Randomized Phase II Trial of Inhaled Budesonide versus Placebo in High-Risk Individuals with CT Screen Detected Lung Nodules. Cancer Prevention Research, 2011, 4, 34-42.	0.7	52
71	Abstract 3670: A randomized, placebo-controlled, phase II, presurgical biomarker trial of celecoxib or exemestane in postmenopausal breast cancer patients. , 2011, , .		1
72	Abstract 3671: Associations between a polymorphic locus in the promoter region of the IGFBP-3 gene, circulating IGFs, mammographic breast density and survival in a 2 Å–2 trial of low-dose tamoxifen and fenretinide in premenopausal women. , 2011, , .		1

#	ARTICLE	IF	CITATIONS
73	Effect of Low-Dose Tamoxifen on Steroid Receptor Coactivator 3/Amplified in Breast Cancer 1 in Normal and Malignant Human Breast Tissue. <i>Clinical Cancer Research</i> , 2010, 16, 2176-2186.	3.2	21
74	Low-dose tamoxifen in the treatment of breast ductal intraepithelial neoplasia: results of a large observational study. <i>Annals of Oncology</i> , 2010, 21, 949-954.	0.6	19
75	Budesonide versus placebo in high-risk population with screen-detected lung nodules: Rationale, design and methodology. <i>Contemporary Clinical Trials</i> , 2010, 31, 612-619.	0.8	9
76	Abstract 1242: Expression of steroid receptor coactivators and HER-2/neu in normal and malignant breast tissue in controls and tamoxifen treated tumors. , 2010, , .		0
77	The effect of transdermal estradiol or oral conjugated oestrogen and fenretinide versus placebo on haemostasis and cardiovascular risk biomarkers in a randomised breast cancer chemoprevention trial. <i>Ecanermedalscience</i> , 2009, 3, 67.	0.6	1
78	Ductal Intraepithelial Neoplasia: Postsurgical Outcome for 1,267 Women Cared for in One Single Institution over 10 Years. <i>Oncologist</i> , 2009, 14, 201-212.	1.9	21
79	Retinoids and Breast Cancer Prevention. <i>Recent Results in Cancer Research</i> , 2009, 181, 77-81.	1.8	19
80	Randomized Dose-Ranging Trial of Tamoxifen at Low Doses in Hormone Replacement Therapy Users. <i>Journal of Clinical Oncology</i> , 2007, 25, 4201-4209.	0.8	64
81	Synthetic retinoid fenretinide in breast cancer chemoprevention. <i>Expert Review of Anticancer Therapy</i> , 2007, 7, 423-432.	1.1	26
82	Does tamoxifen prophylaxis for breast cancer provide long-term prevention?. <i>Nature Clinical Practice Oncology</i> , 2007, 4, 568-569.	4.3	0
83	Chemoprevention of colorectal cancer: an update. <i>Techniques in Coloproctology</i> , 2004, 8, s248-s252.	0.8	14